InflaRx N.V. reported unaudited financial results for the six months ended June 30, 2026, posting a net loss of €16.2 million (€0.17 per share) compared to €22.7 million in the prior year period. The company generated zero revenues due to the discontinuation of GOHIBIC sales activities in December 2025. Operating expenses decreased significantly, with research and development costs falling by €5.3 million to €8.9 million and general and administrative expenses dropping by €2.6 million to €5.7 million. In May 2026, InflaRx completed an underwritten registered direct offering of 75,000,000 ordinary shares at $2.00 per share, raising net proceeds of €119.3 million ($140.4 million). As of June 30, 2026, the company held €146.6 million in cash and cash equivalents plus €11.8 million in marketable securities, providing a total liquidity position of approximately €158.4 million sufficient to fund operations through 2029. The biopharmaceutical company develops anti-inflammatory therapeutics targeting the complement system, including the oral C5aR inhibitor izicopan and the monoclonal antibody vilobelimab.

InflaRx N.V. is assessing a broadened development and registrational strategy for ANCA-Associated Vasculitis (AAV) in Europe following the European Medicines Agency's (EMA) recommendation on June 26, 2026, to revoke the marketing authorization for Tavneos. The company intends to engage with the EMA regarding its anti-C5a antibody vilobelimab and next-generation oral C5aR inhibitor izicopan to determine the most efficient development pathway. InflaRx is a biotechnology company that develops therapies for inflammatory and autoimmune diseases.